Skip to main content
CALAOTCdelisted

Calithera Biosciences, Inc.

Biopharma developer (SEC filing verified)·Phase 2·South San Francisco, CA, United States·CEO: Chief Executive Officer
OncologyRare DiseaseImmunologyRespiratory

CALA evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for CALA—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

5.8/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

$1K

Cash Runway

9.1 mo

Next Catalyst

Financial data as of Dec 31, 2022.

Tracking 3 pipeline candidates · 4 clinical trials for Calithera Biosciences, Inc..

Run Calithera Biosciences, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Calithera Biosciences, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway2.5

9.1 months

Financial Health8.8

D/E 0.41

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Regulatory

Financials

Institutional Holdings

Source: SEC Form 13F · as of Sep 2025

Institutional holders

1

Total value held

$0

HolderSharesValue
ameriflex group, inc.36$0

Short Interest

as of May 20, 2026
% of float
8.9%
Days to cover
0.8
Shares short
417,277
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

CALA short interest

Frequently asked questions

What is Calithera Biosciences, Inc.'s lead drug candidate?

Calithera Biosciences, Inc.'s most advanced tracked candidate is INCB001158 (Phase 1) for Oncology and hematology indications.

Who is the CEO of Calithera Biosciences, Inc.?

Chief Executive Officer is the chief executive officer of Calithera Biosciences, Inc. (CALA).

Where is Calithera Biosciences, Inc. headquartered?

Calithera Biosciences, Inc. (CALA) is headquartered in South San Francisco, CA, United States.

What therapeutic areas does Calithera Biosciences, Inc. focus on?

Calithera Biosciences, Inc. develops therapies across Oncology, Rare Disease, Immunology, Respiratory.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.